Am Fam Physician. 2008 May 15;77(10):1372.
Original Article: Dupuytren's Disease: Diagnosis and Treatment
Issue Date: July 1, 2007
Available at: http://www.aafp.org/afp/20070701/86.html
to the editor: In the article on Dupuytren's disease, Drs. Trojian and Chu describe a procedure for injecting lidocaine 2% (Xylocaine) followed by triamcinolone acetonide (Kenalog) for the treatment of early disease. The accompanying footnote (“Lidocaine will precipitate triamcinolone; therefore, do not mix the two agents.”) caught me by surprise as I have been mixing these two agents in the same syringe for soft tissue and joint injections for many years without incident.
A survey of 835 rheumatologists found that 65.9 percent of them (and 74.7 percent of rheumatologists who trained after 1985) combine lidocaine and steroids for injection.1 Textbooks describing soft tissue and joint injection technique also recommend combining lidocaine and a steroid in the same syringe.2,3 The package inserts from steroid suspensions caution against mixing the steroid with lidocaine to avoid physical incompatibilities. Flocculation may be seen in the syringe when the parabens in multi-dose bottles of lidocaine are mixed with steroids.4 Although it is theorized that this precipitation may increase the risk of post-infection flare, this has not been proven. Using preservative-free, single-use vials of lidocaine may avoid precipitation in the syringe, but whether this influences the rate of post-injection flare has not been studied.
There are several potential advantages to combining lidocaine and a steroid in a single injection. Diluting the steroid in lidocaine may reduce the pain of injection. It also allows the medication to be distributed to a wider area and may decrease the risk of local skin atrophy. The addition of lidocaine to a steroid injection can add diagnostic information as in cases where it is injected subacromially for rotator cuff tendonitis.
Although some concerns about the effect of steroid precipitation on the risk of post-injection flares argue against combining steroids and lidocaine for soft tissue and joint injections, there is no evidence to discourage this common and useful practice.
Author disclosure: Nothing to disclose.
REFERENCESshow all references
1. Centeno LM, Moore ME. Preferred intraarticular corticosteroids and associated practice: a survey of members of the American College of Rheumatology. Arthritis Care Res. 1994;7(3):151–155....
2. Wise C. Arthrocentesis and injection of joints and soft tissues. In: Harris ED, ed. Kelly's Textbook of Rheumatology. 7th ed. Philadelphia, Pa.: Saunders, 2005:692–699.
3. Kern DE. Shoulder and elbow pain. In: Barker LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2003:1027–1048.
4. Pfenninger JL. Joint and soft tissue aspiration and injection (arthrocentesis). In: Pfenninger JL, Fowler GC. Pfenninger and Fowler's Procedures for Primary Care. 2nd ed. St. Louis, Mo., 2003:1480–1481,2028,2033.
editor's note: Dr. Schechtman is correct. The comment about not combining lidocaine and triamcinolone in the same syringe was added to the article during editing, based on unreferenced advice to this effect in an article on injecting the nodules of Dupuytren's disease.1 Further investigation after receiving Dr. Schectman's letter leads us to conclude that this advice is unwarranted, and is indeed counter to the practice and experience of many of us. We apologize to Drs. Trojian and Chu for any embarrassment we may have caused. The footnote has been deleted from the online version of this article.
JAY SIWEK, MD, Editor
1. Ketchum LD, Donahue TK. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. J Hand Surg [Am]. 2000;25(6):1157–1162.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions